HealthcareHealthcare ServicesHealthcare Research, Analytics & Technology

Vimta Labs Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 62 filings·Updated 13 Oct 2026
Showing 10 of 62 filings.
13 Oct 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

No dematerialisation/rematerialisation requests received in the reporting quarter

Requests status

  • Registrar and Share Transfer Agent confirms no dematerialisation/rematerialisation requests were received in the reporting quarter.
Filed 15:09View Source
30 Sept 20261 filing
Insider Trading / SASTClosure of Trading Window

Vimta Labs Ltd - Closure of Trading Window

Vimta Labs Ltd - Closure of Trading Window

Filed 11:39View Source
16 Sept 20261 filing
Company UpdateAllotment of Securities

Vimta Labs Allots 12,955 ESOP Shares; paid-up capital increases

ESOP allotment details

  • 12,955 equity shares allotted under Vimta Labs ESOP Plan 2021.
  • Face value Rs 2 per share; total issued capital increases to Rs 8,93,99,718.
  • Paid-up capital rises to Rs 8,93,99,718; equity shares total 4,46,99,859.
  • Allotted shares rank pari-passu with existing shares; listing formalities in progress.
  • Date of issue: 16 September 2026.
Filed 15:50View Source
8 Sept 20261 filing
Company UpdateAnalyst / Investor Meet

Vimta Labs Ltd files Analyst / Investor Meet update

Meeting Details

  • Event type: Analyst / Investor Meet.
  • Issuer: Vimta Labs Ltd.
  • Purpose: investor interaction with analysts.
Filed 18:23View Source
2 Sept 20261 filing
Company UpdateCredit Rating

CARE Ratings Reaffirms Vimta Labs' Bank Facilities with Stable Outlook

Rating Action

  • Reaffirmed ratings on Vimta's bank facilities; no rating change.

Instruments / Facilities Rated

  • Fund-based LT Term Loan ₹25.50 crore rated CARE A; Stable.
  • Fund-based / CC/WCDL/OD/LC/BG ₹34.00 crore rated CARE A; Stable / CARE A1.
  • Non-fund-based ST Loan Equivalent Risk ₹1.78 crore rated CARE A1.

Rationale

  • Established CRTO leader with diversified pharma, preclinical, food, and electronic testing services.
  • FY26 PBILDT margin 35.26%, PAT margin 18.86%, supported by efficient operations.
  • Healthy capital structure with gearing 0.01x and robust debt protection metrics.
  • Nil working capital limit utilisation and ₹69 crore cash and cash equivalents as of FY26.
  • Regulatory risk due to GXP/GMP/GCP/GLP requirements necessitating capex.
  • Biologics segment investment, with revenue expected by FY27-end; lab expansion capex planned.

Outlook

  • Outlook Stable, aligned with profitability and conservative capital structure.

Rating Sensitivities

  • Positive: turnover growth and higher biologics contribution sustaining asset turnover above 1.0x.
  • Negative: TOI/PBILDT margin decline below 20% or gearing above 0.35x.
  • Regulatory hurdles adversely affecting operations.

Material Change Since Last Rating

  • Rating reaffirmed; no material change in outlook.
Filed 19:06View Source
1 Sept 20262 filings
Company UpdateGeneral

Vimta Labs clarifies stock volume rise is market-driven; confirms all material disclosures made

Share volume clarification

  • Clarifies volume rise across exchanges is not due to company-specific news.
  • States all material disclosures under Regulation 30 SEBI LODR were made within timelines.
  • No events or price-sensitive information has been withheld.
  • Movement attributed to market factors rather than company performance.
  • Signed by Sujani Vasireddi, Company Secretary & Compliance Officer.
Filed 13:08View Source
Company UpdateClarification

The Exchange has sought clarification from Vimta Labs Ltd on September 01, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 12:33
31 Aug 20262 filings
Company UpdateSpurt in Volume

Significant increase in volume has been observed in Vimta Labs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Vimta Labs Limited has submitted their response.

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 19:08View Source
Company UpdateSpurt in Volume

Significant increase in volume has been observed in Vimta Labs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 18:01View Source
29 Aug 20261 filing
Company UpdateAnalyst / Investor Meet

Vimta Labs Analyst/Investor Meet announced under Company Update filing

Meeting Details

  • Event: Analyst/Investor Meet for Vimta Labs Ltd.

Participants

  • Key company participants: management team (roles unspecified).

Purpose

  • Purpose: investor interaction and company updates discussion.
Filed 10:17View Source
Showing 10 of 62 filings